Reversible Severe Eosinophilic Endomyocardial Fibrosis During Pregnancy
A Case Report

Marc Pineton de Chambrun, MD, Philippe Charron, MD, PhD, Danièle Vauthier-Brouzes, MD, Philippe Cluzel, MD, PhD, Julien Haroche, MD, PhD, Jean-Emmanuel Kahn, MD, PhD, Zahir Amoura, MD, MSc, and Fleur Cohen Aubart, MD, PhD

Abstract: Idiopathic hypereosinophilic syndrome (HES) is a condition of unknown origin characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. Cardiac involvement is rare and threatening accounting for 33% to 43% of death in HES. Management of pregnant patients with HES is challenging and has rarely been reported, particularly in the setting of heart failure.

We here report on the case of a 29-year-old woman with HES who developed severe endomyocardial fibrosis with heart failure during pregnancy. Outcome was favorable under treatment with prednisone and azathioprine.

This case illustrates a favorable outcome of endomyocardial fibrosis during pregnancy.

(Abbreviations: FIP1L1 = factor interacting with PAPOLA and CPSF1, HES = hypereosinophilic syndrome, JAK2 = janus kinase 2, LV = left ventricle, MRI = magnetic resonance imaging, NYHA = New York Heart Association, PDGFRA = α-type platelet-derived growth factor receptor, WA = week of amenorrhea.)

INTRODUCTION

Idiopathic hypereosinophilic syndrome (HES) is a condition of unknown origin characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. Cardiac involvement is rare and threatening accounting for 33% to 43% of death in HES. Management of pregnant patients with HES is challenging and has rarely been reported, particularly in the setting of heart failure.

CASE REPORT

A 29-year-old woman returning from Saint Martin Island presented in April 2013 with dyspnea and chest pain, which were then diagnosed as clinically suspected eosinophils-associated myocarditis because of pulmonary edema, elevated troponin, and high eosinophil blood count. She received 3 pulses of steroids and was also treated with 2 doses of ivermectine as *Strongyloides* serology was positive. In July 2013, troponin dosage, eosinophil blood count, echocardiography, and cardiac magnetic resonance imaging (MRI) were normal.

In December 2013, when she was pregnant with 18 weeks of amenorrhea (WA), she was admitted to the intensive cardiologic unit department for respiratory distress. Electrocardiogram was normal but chest x-ray was consistent with pulmonary edema. Blood tests showed elevated ultrasensitive troponin: 139 ng/mL (N < 0.14), NT-proBNP: 3350 ng/L, and markedly increased circulating eosinophils at 4.75 × 10^9/L. Renal and liver tests were normal. A transsthoracic echocardiogram revealed hyperkinetic left ventricular with subtotal thrombotic occlusion of left ventricle (LV) (Figure 1C and E). Systolic pulmonary artery pressure was elevated at 75 mm Hg. Cardiac MRI revealed diffuse LV endomyocardial fibrosis with circumferential intraventricular adherent LV thrombus (Figure 1A).

No extra-cardiac involvement (i.e., neurological, pulmonary, cutaneous, or gastrointestinal) was detected. Screening for all etiology of secondary or clonal eosinophilia was negative including extended lymphoid phenotyping, janus kinase 2 mutation (JAK2), and factor interacting with PAPOLA and CPSF1 (FIP1L1)–α-type platelet-derived growth factor receptor (PDGFRA) transcript fusion testing. Bone marrow biopsy was also normal despite marked eosinophil infiltration. The diagnosis of idiopathic hypereosinophilic syndrome (HES)-associated severe endomyocardial fibrosis was suspected.

Symptomatic treatment included diuretics, low-dose β-blockers, and curative anticoagulation with enoxaparin. Three intravenous pulses of 1 g methylprednisolone were administered followed by 1 mg/kg/d of oral prednisone. She quickly improved, keeping a class III New York Heart Association (NYHA) dyspnea. Despite persistent severe postcapillary pulmonary hypertension, pregnancy was continued. One month later, echocardiography was stable and eosinophils were still at normal counts.
1.0 g/L (Figure 2). Azathioprine was introduced (2 mg/kg/d) and steroids were progressively tapered down.

At 35 WA, she underwent a C-section because of fetal heart rate abnormalities. The newborn’s weight was 1900 g (between 10th and 25th percentile), and birth blood pH and lactate were 7.26 and 3 mmol/L, respectively. Early outcome was favorable for the mother and the baby. Under azathioprine, 6 months after delivery, she was asymptomatic, and eosinophils blood count as well as echocardiography and cardiac MRI had normalized (Figure 1).

**DISCUSSION**

Here we described a case of severe eosinophilic endomyocardial fibrosis occurring during pregnancy. Under treatment with steroids and azathioprine, despite severe pulmonary hypertension, pregnancy had a favorable outcome. Six months after delivery, the patient had fully recovered from endomyocardial fibrosis.

Acquired eosinophilia is classified as secondary (parasitic, drug-induced, vasculitis, ...), clonal (myeloid or lymphoid
malignancies, . . . ), or idiopathic. After exclusion of secondary causes of eosinophilia, a stepwise diagnostic algorithm should include peripheral blood screening for FIP1L1–PDGFRA transcript fusion, bone marrow biopsy, JAK2 mutation testing, peripheral blood lymphocytes phenotyping, and T-cell receptor gene rearrangement studies in order to discard clonal causes of eosinophilia. The diagnostic of HES can be advocated in case of negativity of all the test cited above.1 Cardiac involvement of HES is rare and life-threatening, accounting for 33% to 43% of deaths, with a frequency reported from 5% to 72%.2–4

Treatment of chronic acquired eosinophilia strongly depends on whatever the cause of eosinophilia. In clonal eosinophilia, treatment mainly consists of kinase inhibitor. In HES, corticosteroids remain the first-line treatment and corticosteroid-sparing agents nowadays mainly rely on hydroxyurea, interferon-α, or cyclosporine. Despite a promising preliminary study, mepolizumab and other anti-interleukin-5 antibodies have not been approved in this setting. No specific drugs have been advocated in cardiac involvement of HES except for heart failure treatment and antiaggregation therapy because of the high frequency of intracardiac thrombus. The use of azathioprine as a corticosteroid-sparing agent for HES has been only anecdotally reported without clear information about its efficacy.5

Only 3 cases of pregnancy during HES have been reported, all with favorable outcomes.5–7 Two patients were treated with steroids (maintenance doses between 20 and 25 mg/d) and the last one was left untreated. One of those patients had a cardiac involvement consisting in right and LV thrombus but without cardiac failure. Cardiac MRI was not performed because of pregnancy. Our patient suffered from a particularly severe cardiac manifestation of HES during pregnancy. Steroids allowed quick improvement but the patient still complained of NYHA III dyspnea. The persistence of pulmonary hypertension and elevated circulating eosinophils counts led us to introduce a corticosteroid-sparing agent, namely, azathioprine, because of the safety profile during pregnancy. Outcome was good for the mother and baby. Six months after delivery, echocardiography and cardiac MRI confirmed full resolution of interventricular thrombus with regression of endomyocardial fibrosis.

In conclusion, even in a severe cardiac involvement of HES, pregnancy can successfully be conducted using steroids and azathioprine. This study has been approved by the ethics committee: Comité de Protection des Personnes (CPP) “Ile-de-France VI,” Hôpital Pitié-Salpêtrière, Paris, France.

ACKNOWLEDGMENTS

The authors would like to thank Professor David Grant for his help in editing the manuscript.

REFERENCES

1. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010;85:158–164.
2. Podjasek JC, Butterfield JH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res. 2013;37:392–395.
3. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;359:1215–1228.
4. Ogbugo PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–1325.
5. Ault P, Cortes J, Lynn A, et al. Pregnancy in a patient with hypereosinophilic syndrome. Leuk Res. 2009;33:186–187.
6. Darki A, Kodali PP, McPheeters JP, et al. Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis. Tex Heart Inst J. 2011;38:163–165.
7. Albrecht AE, Hartmann BW, Kurz C, et al. Idiopathic hypereosinophilic syndrome and pregnancy. Acta Obstet Gynecol Scand. 1997;76:485–486.

FIGURE 2. Eosinophils blood count evolution during pregnancy.